Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 501 - 550 of 1868 results
- Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.
- Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme.
- Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells.
- Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
- Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
- A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study.
- N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors.
- A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.
- Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
- Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor.
- Immunogenic gangliosides in human ovarian carcinoma.
- Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
- CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models.
- A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells.
- Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
- Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
- Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer.
- Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.
- Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
- Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down.
- The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
- Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials.
- Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells.
- Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent.
- Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
- Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.
- Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.
- Murine dendritic cells modified with CXCL10 gene and tumour cell lysate mediate potent antitumour immune responses in mice.
- Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.
- Selectively oncolytic mutant of HSV-1 lyses HeLa cells mediated by Ras/RTN3.
- Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes.
- Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
- Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.
- Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity.
- Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
- A CD46-binding Chimpanzee Adenovirus Vector as a Vaccine Carrier.
- Five-year Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy for Treatment of Prostate Cancer.
- Cell-penetrating autoantibody induces caspase-mediated apoptosis through catalytic hydrolysis of DNA.
- Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
- Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions.
- Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
- Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
- An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.
- Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
- mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
- VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
- A three-dimensional assay for measurement of viral-induced oncolysis.
- Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis.
- Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins.
- Complete remission of multiple myeloma after autoimmune hemolytic anemia: possible association with interferon-alpha.